Joshua Hernandez
The treatment of multiple sclerosis is growing more complex as new disease-modifying medications become available. Using consensus statements is thus recommended. The current consensus statement, developed by the study group on demyelinating illnesses of the Spanish Society of Neurology, updates earlier consensus statements on the disease. The current study lists and assesses the drugs currently approved for multiple sclerosis as well as their official indications, as well as therapyrelated features such as activity, early treatment, maintenance, follow-up, treatment failure, medication adjustments, and unusual therapeutic scenarios. This consensus statement includes recommendations for initial therapy and changes in drug medication, as well as additional comments on induction and combined therapy and practical aspects of the use of these drugs. These recommendations cover a wide range of demyelinating diseases, from isolated demyelinating syndromes to the various forms of multiple sclerosis.